**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 7245**

**Columns:** **PROSPECTIVE STUDY**

**Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis**

García-Compeán D *et al*Subclinical abnormal glucose tolerance and cirrhosis

Diego García-Compeán, Joel Omar Jáquez- Quintana,Fernando Javier Lavalle-González,José Alberto González-González,Linda Elsa Muñoz-Espinosa,Jesús Zacarías Villarreal-Pérez,Héctor J Maldonado-Garza

**Diego García-Compeán, Joel Omar Jáquez- Quintana, José Alberto González-González, Héctor J Maldonado-Garza**, Gastroenterology Service and Department of Internal Medicine, University Hospital "Dr. Jose E. Gonzalez” and Medical School, Universidad Autónoma de Nuevo León, Monterrey 64320, Mexico

**Fernando Javier Lavalle-González, Jesús Zacarías Villarreal-Pérez,** Endocrinology Service and Department of Internal Medicine, University Hospital "Dr. Jose E. Gonzalez” and Medical School, Universidad Autónoma de Nuevo León, Monterrey 64320, México

**Linda Elsa Muñoz-Espinosa,** Liver Unit, University Hospital "Dr. José E. González” and Medical School, Universidad Autónoma de Nuevo León, Monterrey 64320, México

**Author contributions:** García-Compeán D designed wrote and coordinated the research; Jáquez- Quintana JO and González-González JA evaluated patients at inclusion and follow-up; Lavalle-González FJ and Villarreal-Pérez JZ participated in laboratory testings and revision of the text; Muñoz-Espinosa LE and Maldonado- Garza H reviewed the text.

**Supported by** Gastroenterology and Endocrinology Services of the University Hospital, Universidad Autónoma de Nuevo León, Monterrey, México

**Correspondence to: Diego García-Compeán, MD**, Gastroenterology Service and Department of Internal Medicine, University Hospital "Dr. Jose E. Gonzalez” and Medical School, Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey 64320, México. digarciacompean@prodigy.net.mx

**Telephone:** +52-81-83487315 **Fax:** +52-81-89891381

**Received:** November 10, 2013 **Revised:** February 5, 2014

**Accepted:** March 19, 2014

**Published online:**

**Abstract**

**AIM**: To determine if subclinical abnormal glucose tolerance (SAGT) has influence on survival of non diabetic patients with liver cirrhosis.

**METHODS:** In total, 100 patients with compensated liver cirrhosis and normal fasting plasma glucose were included. Fasting plasma insulin (FPI) levels were measured, and oral glucose tolerance test (OGTT) was performed. According to OGTT results two groups of patients were formed: with normal glucose tolerance (NGT) and with SAGT. Patients were followed every three months. The mean follow-up was 932 d (range of 180-1925). Survival was analyzed by the Kaplan-Meyer method, and predictive factors of death were analyzed by regression testing Cox’s proportional hazard model.

**RESULTS**: Of the included patients, 30 showed NGT and 70 SAGT. Groups were significantly different only in age, INR, FPI and HOMA2-IR. Patients with SAGT showed lower 5-year cumulated survival than NGT patients (31.7 *vs* 71.6%, *P* = 0.02). Differences in survival were significant only after 3 years of follow up. SAGT, Child-Pugh group B, and high Child-Pugh and MELD scores were independent predictors of death. The causes of death in 90.3% of cases were due to complications related to liver disease.

**CONCLUSION**: SAGT was associated with lower survival. SAGT, Child-Pugh group B, and high Child-Pugh and MELD scores were independent negative predictors of survival.

©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Diabetes mellitus; Liver cirrhosis; Oral glucose tolerance test; Survival; Glucose metabolism disorders

**Core tip:** In this controlled prospective long term study we demonstrated that subclinical forms of abnormal glucose tolerance (IGT) or diabetes mellitus (DM) may influence survival of non diabetic cirrhotic patients. Previously it had been demonstrated that clinically overt DM is associated with low survival of cirrhotic patients. This issue is important since a high proportion of cirrhotic patients (about 70%) without history of DM and normal fasting plasma glucose has subclinical abnormal glucose tolerance. The use of oral glucose tolerance test for early recognition and treatment of DM may improve prognosis of these patients.

García-Compeán D, Jáquez- Quintana JO,Lavalle-González FJ,González-González JA,Muñoz-Espinosa LE,Villarreal-Pérez JZ,Maldonado-Garza HJ。 Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Overt diabetes mellitus (DM) has been reported in 21%-30% of patients with liver cirrhosis (LC)[1]. DM may arise from a progressive disorder of insulin secretion in the presence of liver and muscle resistance to insulin[2,3].

DM is related to LC in two ways: (1) type 2 diabetes mellitus (T2DM) (often associated with metabolic syndrome) causes non alcoholic fatty liver disease (NAFLD) (steatosis, steatohepatitis, LC, and hepatocellular carcinoma)[4-7]; and (2) DM may develop as a complication of LC, which is known as “hepatogenous diabetes” (HD)[8,9]. As liver disease advances, DM becomes clinically evident[10,11]. T2DM and HD are associated with increased risk of complications of chronic liver diseases and mortality[7,9,12-17].

On the other hand, subclinical abnormal glucose tolerance disorders (SAGT), such as impaired glucose tolerance or DM (called subclinical since they are detected only by means of an oral glucose tolerance test), may be observed in 45 and 22%, respectively, of patients with LC and no history of DM[18,19]. Therefore, the prevalence of DM and impaired glucose tolerance (IGT) may be underestimated when only fasting plasma glucose (FPG) levels are taken into account. Our group has recently published a study determining the prevalence of T2DM, DH and IGT in patients with LC who underwent oral glucose tolerance test (OGTT). In total, 86% of the cases had either overt or subclinical IGT and DM, with or without insulin resistance (IR)[18].

The negative influence of the SAGT on the survival of cirrhotic patients was demonstrated in one study carried out in Japan, which found that patients with IGT or DM diagnosed by OGTT, had a significantly lower 5-year survival rate[20]. However, similar findings have not been reported by others elsewhere.

The aims of this study were: (1) to evaluate if SAGT has any influence on survival of patients with compensated LC and normal FPG levels; and (2) to identify mortality predictors.

**MATERIALS AND METHODS**

***Patients***

Patients with LC, who were seen in our hospital from August 2007 to August 2012, were prospectively evaluated. Only those with normal FPG (< 100 mg/dL), no history of overt DM, with clinical or histological diagnosis of LC, aged over 18 years old and without clinically evident complications of liver disease (*e.g.*, esophageal or gastric variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, infection, spontaneous bacterial peritonitis, and moderate to severe ascites), were selected for the study (patients with complications were excluded in order to avoid the effect of medications used for treating them, on glucose metabolism of patients). Clinical diagnosis of LC was made by using a combination of clinical symptoms, laboratory tests and imaging studies (abdominal ultrasonography or CT scan)[21,22]. The etiology of cirrhosis was determined as follows: Alcohol-related cirrhosis was determined when daily alcohol consumption was of > 80 g in men and > 40 g in women for at least 10 years with negative viral, metabolic and autoimmune markers. Diagnosis of hepatitis C virus and B virus related cirrhosis was determined with specific viral markers (HBsAg or anti-HCV). Autoimmune liver disease was diagnosed with specific autoimmune markers (anti-nuclear antibodies, anti-smooth muscle antibodies or liver-kidney anti-microsomal antibodies), meanwhile cryptogenic cirrhosis was established in the absence of any of the causes above described[23].

 Informed consent was obtained from each patient. The protocol was approved by The Research and Ethics Committee of the Faculty of Medicine of the Autonomous University of Nuevo Leon in Monterrey.

***Fasting plasma insulin and OGTT***

Fasting plasma insulin (FPI)levels were measured and OGTT was performed according to the WHO criteria[24]. Patients were fasted for at least 12 hours, and baseline plasma glucose was measured; then, they were given an oral glucose load (75 g). Additionally, plasma glucose (PG) levels were measured every 30 min for 2 h. The results were interpreted as follows: a) normal glucose tolerance (NGT) if 2-h PG was < 140 mg/dL; IGT if 2-h PG was between 140 mg/dL and 200 mg/dL; and DM if 2-h PG was > 200 mg/dL. Plasma HbA1c was not used for diagnosing diabetes mellitus due to its low sensitivity reported in cirrhotic patients[19].

FPI was measured by using the electrochemiluminescence method (normal values: 5–20 μU/mL). HOMA2-IR index (Homeostasis Model Assessment 2-Insulin Resistance Index) was calculated using the following online software (<http://www.dtu.ox.ac.uk/homacalculator/index.php>).

***Assessments***

The following data were recorded in a data base specially designed for the study: gender, age, and family history of DM as well as laboratory blood tests results (serum hemoglobin, leukocytes, platelets, BUN, creatinine, albumin, bilirubin, aspartate aminotransferase, γ- glutamyltranspeptidase, alkaline phosphatase, cholesterol, triglycerides, and INR). The body mass index (BMI) was calculated, and construed as follows: normal if < 24.9, overweight between 25 and 29.9, and obesity if > 30[25]. Liver function was estimated using Child-Pugh and MELD (Model for End-Stage Liver Disease) classifications[26,27].

***Follow-up***

All patients were followed-up every 3 mo in the outpatient department. A full clinical examination was made in each interview. Laboratory blood testing (serum hemoglobin, hematocrit, blood cell count, glucose, creatinine, BUN, liver function tests and coagulation tests) was also performed. Moreover, plasma alpha-fetoprotein and liver ultrasonography were performed every 6 months. Additionally, hospital admissions were recorded during which clinical course of the patient was determined. Patients or relatives of them were contacted by telephone when he or she did not attend to appointments. Callings were done in order to determine the clinical status of the patient, or to inquire whether their death occurred.

During follow-up patients were treated with life style and diet modifications, and in particular cases with oral hypoglycemic agents or insulin administration. No antidiabetic medication was given to those with impaired glucose tolerance.

***Statistical analysis***

Continuous variables were expressed as means and standard deviations, while non-continuous variables as medians and ranges. Categorical variables were expressed as relative proportions. Intergroup comparisons were made by Student *t*, χ*2* and Mann-Whitney tests. Variables were analyzed using regression testing Cox’s proportional hazard model in order to determine independent predictive factors of mortality[28]. Only the variables that were statistically significant in univariate analysis were analyzed in multivariate analysis. The results were expressed as hazard ratios (HR) with 95% confidence intervals, and the p-value was calculated.

The cumulative survival was analyzed using the Kaplan-Meier method, and the curves were compared using log-rank test. A *P*-value of less than 0.05 was considered statistically significant. All statistical analyses were done using the statistical package SPSS v17.0 (Chicago, Illinois, United States).

**RESULTS**

***Patient population***

Of 293 cirrhotic patients evaluated, 124 (42.3%) met the inclusion criteria. However, 24 (8.1%) of them were not finally included due to the following reasons: 13 refused to participate into the study, 8 found difficult to attend consultation because they lived in another state, and 3 did not attend their appointments for performing OGTT (Figure 1).

Finally, 100 (34.1%) patients were included into the study. Their clinical and biochemical characteristics are shown in Table 1. Although BMI is not the best procedure for assessing nutritional status in cirrhotic patients (particularly in those with ascites), this method showed that most of them (69%) were overweight or obese. The etiology of cirrhosis was predominantly alcoholic and cryptogenic (47% and 26%, respectively). The diagnosis of LC was confirmed by liver biopsy in 44% of cases. In total, 47% and 53% of patients were assigned into the groups A and B of the Child-Pugh classification. The mean Child-Pugh score was 6.9 ± 1. 8 points and the mean MELD score was 8.9 ± 4.8. The mean values of FPI levels and HOMA2-IR Index were 15.9 ± 10.2 µU/mL, and 2.67 ± 1.6 respectively.

***Clinical characteristics and survival rate of patients***

Two groups were formed according to the results of OGTT: those with NGT (30 patients) and those with SAGT (70 patients, 44 with IGT and 26 with DM). Clinical and biochemical characteristics are shown in Table 1. SAGT patients were significantly older and had higher values of INR, FPI and HOMA2-IR. Notwithstanding, although Child-Pugh and MELD scores were mildly higher in patients with SAGT, these differences were not statistically significant.

***Follow-up***

The mean follow-up was 932 d (range of 180-1925). At the end of follow up, 19 (19%) patients (5 NGT patients and 14 SAGT patients) developed overt IGT (7 cases) or overt DM (12 cases). All patients with SAGT were prescribed dietary and life style modifications. At different times of follow up, oral anti diabetic medications were prescribed in 6, and subcutaneous insulin was prescribed in 2 out of 12 patients with overt DM.

In total, 49% of alcoholic patients consistently stopped alcohol consumption, the 47% of patients with hepatitis C virus infection were treated with antiviral therapy, the 50% and 90% of patients with hepatitis B virus infection or autoimmune liver disease were treated. There were no dropouts.

***Cumulative survival***

The mean survival time was 1448 d (range: 1256-1925) in the patients with NGT, while it was 1116 (range 990-1790) in the patients with SAGT (*P* = 0.045). Cumulative survival curve of patients with NGT and SAGT is shown in Figure 2. SAGT patients had significantly lower survival (*P* = 0.02).

One to 5-year survival rates are shown in Table 2. Statistically significant differences were observed only after three years of follow-up. Increasing differences were observed over time until the end of follow up.

***Causes of death***

In total 31 patients died (5 form NGT group and 26 form SAGT group). The causes of death are shown in Table 3. Twenty eight (90.3%) died due to the following complications related to liver disease: 8 due to esophageal variceal bleeding (25.8%), 6 due chronic liver failure (19.3%), 5 due to spontaneous bacterial peritonitis and other infections (16.2%), 5 due to hepatorenal syndrome (16.2%) and 4 due to hepatocellular carcinoma (12.9%). Additionally, 2 of the remaining patients died due to renal impairment (6.4%), and 1 due to cardiovascular disease (3.2%). There were no significant differences in the cause of death among patients with NGT vs. those with SAGT.

***Predictors of death***

Serum creatinine, albumin, INR, Child-Pugh group B, Child-Pugh and MELD scores, SAGT as well as FPI were statistically significant according to univariate analysis. However, only Child-Pugh group B (HR = 8.2, 95%CI: 2.0-28.5, *P* = 0.02), Child-Pugh score (HR = 10.2, 95%CI: 2.4-21.9, *P* = 0.008), MELD score (HR = 12.3, 95%CI: 6.4-33.6, *P* = 0.001), and SAGT (HR = 3.2, 95%CI: 2.8-54.2, *P* = 0.01) were independent predictors of survival according to multivariate analysis (Table 4).

D**ISCUSSION**

Our study suggests that SAGT may have negative impact on the survival of patients with LC, as those who showed this abnormality had lower 5-year survival than those who had NGT. Significant differences in survival were observed after 3 years of follow-up (Table 2). These results are consistent with another study, carried out ​​in Japan, with 58 cirrhotic patients without overt DM who underwent OGTT[20]. In this study, 5-year survival rate was lower in patients with IGT and DM compared to those with NGT. Albumin and abnormal OGTT were independent negative predictors of survival[20]. Despite the similarities in results of both studies, ours differs in the following points: (1) 74% of our patients had alcoholic and cryptogenic cirrhosis, while 78.5% of patients in the Japanese study had viral etiology (HBV and HCV). The causes of chronic liver disease in our patients were identical to those observed in most western countries, where alcohol and metabolic syndrome are the predominant causes (especially nowadays, that the frequency of obesity and nonalcoholic fatty liver disease have dramatically increased), while viral etiology is predominantly observed in Asiatic countries[29,31]; (2) At time of inclusion, our patients did not have liver-related complications, whereas in the Japanese study, up to 30% had ascites and hepatic encephalopathy, and finally (3) The number of patients in our study was almost twice.

The mechanism by which SAGT may be involved in the occurrence of death of cirrhotic patients is difficult to explain. DM may induce progression of liver fibrosis, inflammation and liver failure, or may increase cardiovascular complications and atherosclerosis. In a study with virus C-infected patients, IR and DM were significantly associated with liver fibrosis[32]. Furthermore, in other reports, it has been suggested that DM can increase fibrosis, incidence of hepatocellular carcinoma, and resistance to antiviral therapy in patients with hepatitis C virus[33]. DM may be involved in the progression of liver fibrosis and inflammation through diverse mechanisms: it is likely that adipokine production (such as leptin and TNF-alpha, which activate inflammatory pathways exacerbating liver injury) is increased by insulin resistance[34-36]. Leptin and oxidative stress associated with liver inflammation may activate the transforming growth factor beta 1 (TGF-β1), which is one of the most potent profibrogenic cytokines produced in the liver. TGF-β1 activates the liver stellate cells which are the major source of collagen I and III and extracellular matrix proteins[37-39]. In our study, SAGT as well as high Child-Pugh and MELD scores were independent predictors of death. This suggests that SAGT combined with other etiologic agents of liver cirrhosis might have induced liver failure and death.

On the other hand, as it has been pointed out in other publications, most of our patients with SAGT died from liver disease related complications[9,20,40] (Table 3). DM increases the incidence of severe infections by inducing immunosuppression. Cirrhotic patients with DM have a higher prevalence of infections compared to non-diabetic ones. In a recent study, spontaneous bacterial peritonitis was more frequent in patients with cryptogenic cirrhosis (which is associated with DM) compared to those with cirrhosis of other causes[41]. These infected patients had higher in-hospital mortality due to sepsis, liver failure, and hepatorenal syndrome[42]. In addition, DM may increase the risk of variceal bleeding, as postprandial hyperglycemia that occurs in diabetic patients produces splanchnic vasodilatation and increases the flow and pressure of the porto systemic venous system[43]. Also, esophageal variceal bleeding increases the risk of infection and death by inducing bacterial intestinal translocation[44]. The DM has been also associated with an increased risk of hepatic encephalopathy (HE). A significant association between malnutrition and diabetes with HE was observed in a study with cirrhotic patients[45]. In multivariate analysis, Child-Pugh classification, malnutrition and DM showed independent correlation with HE. Plasma ammonium ion levels were related to insulin resistance and muscle mass. Authors concluded that nutritional status and insulin resistance might be implicated in the pathogenesis of HE.[45].

 On the other hand, some authors reported low frequency of diabetic complications in cirrhotic patients[46]. However, these observations have been recently challenged: in two published studies, patients with chronic hepatitis C compared to controls, showed significant higher carotid intima media thickness, greater number of carotid plaques and carotid atherosclerosis affection[47,48].In one of these studies[47] , older age and severe hepatic fibrosis were independently associated to early carotid atherosclerosis. In the other one[48], diabetes and metabolic syndrome were associated with carotid plaques. The precise prevalence of cardiovascular disease or atherosclerosis, and their role in the induction of death in cirrhotic patients with DM, need to be defined in future well conducted studies .

In our study, we did not observe significant differences in the causes of death among patients with NGT compared to those with SAGT (Table 3).This may be due to the small number of individuals in each group. Some differences might be clearly evident using a larger sample of patients.

Although the negative impact of DM on survival of cirrhotic patients is well known long time ago, the beneficial effects of early detection and treatment of DM and IGT for reducing complications and mortality rates have not been clearly determined. In our study, analysis of this issue was not performed due to the low number of patients. This important point has to be determined in future studies.

In conclusion, SAGT disorders were associated with reduced long term survival in patients with compensated LC and normal FPG. Additionally, SAGT, Child-Pugh group B, and high Child-Pugh and MELD scores were independent negative predictors of survival. These findings suggest that the SAGT may give rise to morbid conditions that increase mortality of patients. According to this, the OGTT is useful for accurate assessment of mortality in non-diabetic cirrhotic patients.

**COMMENTS**

 ***Background***

 Overt diabetes mellitus (DM) may be found in 30% of patients with liver cirrhosis of diverse etiology. Since long time ago, it is known that overt DM is linked to a reduction of survival of patients with liver cirrhosis. Causes of death of these patients are mostly due to liver disease complications. Noneless, 60% of non diabetic patients with liver cirrhosis may have abnormal glucose tolerance disorders, either impaired glucose tolerance (IGT) orDM, after an oral glucose tolerance test.

***Research frontiers***

 The impact of subclinical forms of IGT and DM on survival of cirrhotic patients has not been extensively described. In this paper, the authors demonstrate that patients with these forms of abnormal glucose tolerance have a reduced long term survival than those with normal glucose tolerance. Nevertheless, this study does not allow demonstrating the mechanisms by which abnormal glucose tolerance may reduce survival of patients

***Related publications***

 The impact of subclinical forms of abnormal glucose tolerance on survival of cirrhotic patients has been described in only one study performed in Japan. In this study, patients with IGT and DM detected with oral glucose tolerance test (OGTT), had reduced 5-year survival than those with normal glucose tolerance.

 ***Innovations and breakthroughs***

Most of the patients in the previously published study had cirrhosis of viral etiology and 30% had liver complications while in ours, patients were clinically compensated and most of them had alcoholic and cryptogenic etiology. In addition the sample size of our study was double.

 ***Applications***

The practical applications of the findings of this study are clear: early detection of abnormal glucose tolerance conditions through OGTT allows early treatment of DM and consequently a reduction of complications and mortality of patients. It is suggested the use of OGTT in all patients with liver cirrhosis without previous DM, in order to assess prognosis of survival. Those with DM may be included in a close monitoring and an early treatment program. Future studies concerning the mechanisms by which DM induces death of cirrhotic patients may allow focusing prevention and therapeutic measures.

***Terminology***

Subclinical abnormal glucose tolerance refers to impaired glucose tolerance and diabetes mellitus detected with an oral glucose tolerance test.

***Peer review***

The investigators correlated the subclinical abnormal glucose tolerance and reduced survival in cirrhosis patients, and found the subclinical abnormal glucose tolerance was associated with lower survival.

**REFERENCES**

1 **Hickman IJ**, Macdonald GA. Impact of diabetes on the severity of liver disease. *Am J Med* 2007; **120**: 829-834 [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025]

2 **Petrides AS**, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. *Hepatology* 1994; **19**: 616-627 [PMID: 8119686 DOI: 10.1002/hep.1840190312]

3 **Petrides AS**, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. *Hepatology* 1998; **28**: 141-149 [PMID: 9657106 DOI: 10.1002/hep.510280119]

4 **Lewis JR**, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. *Dig Dis Sci* 2010; **55**: 560-578 [PMID: 20101463 DOI: 10.1007/s10620-009-1081-0]

5**Blendea MC**, Thompson MJ, Malkani S. Diabetes andChronic liver disease: Etiology and pitfalls in monitoring. *Clin Diabetes* 2010; **28**: 139-144 [DOI: 10.2337/diaclin.28.4.139]

6 **Porepa L**, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. *CMAJ* 2010; **182**: E526-E531 [PMID: 20566726 DOI: 10.1503/cmaj.092144]

7 **Loria P**, Lonardo A, Anania F. Liver and diabetes. A vicious circle. *Hepatol Res* 2013; **43**: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]

8 **García-Compean D**, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. *Ann Hepatol* 2009; **8**: 13-20 [PMID: 19221528]

9 **Holstein A**, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. *J Gastroenterol Hepatol* 2002; **17**: 677-681 [PMID: 12100613 DOI: 10.1046/j.1440-1746.2002.02755.x]

10 **Del Vecchio Blanco C**, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. *Diabetes Res Clin Pract* 1990; **8**: 29-36 [PMID: 2153513 DOI: 10.1016/0168-8227(90)90093-9]

11 **Tolman KG**, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. *Diabetes Care* 2007; **30**: 734-743 [PMID: 17327353 DOI: 10.2337/dc06-1539]

12 **Bianchi G**, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. *Hepatology* 1994; **20**: 119-125 [PMID: 8020880]

13 **Lonardo A**, Carulli N, Loria P. HCV and diabetes. A two-question-based reappraisal. *Dig Liver Dis* 2007; **39**: 753-761 [PMID: 17611176]

14 **Quintana JO**, García-Compean D, González JA, Pérez JZ, González FJ, Espinosa LE, Hernández PL, Cabello ER, Villarreal ER, Rendón RF, Garza HM. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. *Ann Hepatol* 2011; **10**: 56-62 [PMID: 21301011]

15 **Harrison SA**. Liver disease in patients with diabetes mellitus. *J Clin Gastroenterol* 2006; **40**: 68-76 [PMID: 16340637 DOI: 10.1097/01.mcg.0000190774.91875.d2]

16 **de Marco R**, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. *Diabetes Care* 1999; **22**: 756-761 [PMID: 10332677 DOI: 10.2337/diacare.22.5.756]

17 **El-Serag HB**, Everhart JE. Diabetes increases the risk of acute hepatic failure. *Gastroenterology* 2002; **122**: 1822-1828 [PMID: 12055590 DOI: 10.1053/gast.2002.33650]

18 **García-Compeán D**, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, Villarreal-Pérez JZ, Maldonado-Garza HJ. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. *Ann Hepatol* 2012; **11**: 240-248 [PMID: 22345342]

19 **Cacciatore L**, Cozzolino G, Giardina MG, De Marco F, Sacca L, Esposito P, Francica G, Lonardo A, Matarazzo M, Varriale A. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. *Diabetes Res* 1988; **7**: 185-188 [PMID: 3402168]

20 **Nishida T**, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. *Am J Gastroenterol* 2006; **101**: 70-75 [PMID: 16405536 DOI: 10.1111/j.1572-0241.2005.00307.x]

21 **Cozzolino G**, Lonardo A, Francica G, Amendola F, Cacciatore L. Differential diagnosis between hepatic cirrhosis and chronic active hepatitis: specificity and sensitivity of physical and laboratory findings in a series from the Mediterranean area. *Am J Gastroenterol* 1983; **78**: 442-445 [PMID: 6869354]

22 **Udell JA**, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM. Does this patient with liver disease have cirrhosis? *JAMA* 2012; **307**: 832-842 [PMID: 22357834 DOI: 10.1001/jama.2012.186]

23 **Caldwell SH**, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999; **29**: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]

24 **Alberti KG**, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; **15**: 539-553 [PMID: 9686693 DOI: 3.0.CO; 2-S']

25 **Nguyen DM**, El-Serag HB. The epidemiology of obesity. *Gastroenterol Clin North Am* 2010; **39**: 1-7 [PMID: 20202574 DOI: 10.1016/j.gtc.2009.12.014]

26 **Pugh RN**, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; **60**: 646-649 [PMID: 4541913 DOI: 10.1002/bjs.1800600817]

27 **Kamath PS**, Kim WR. The model for end-stage liver disease (MELD). *Hepatology* 2007; **45**: 797-805 [PMID: 17326206 DOI: 10.1002/hep.21563]

28 **Cox D**. Regression models and life tables. *J Roy Statist Soc* 1972; **34**: 187–220

29 **Petrasch S**, Stein H, Kosco MH, Brittinger G. Follicular dendritic cells in non-Hodgkin lymphomas: localisation, characterisation and pathophysiological aspects. *Eur J Cancer* 1991; **27**: 1052-1056 [PMID: 1832893 DOI: 10.1016/S0140-6736(08)60383-9]

30 **Angulo P**. GI epidemiology: nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2007; **25**: 883-889 [PMID: 17402991 DOI: 10.1111/j.1365-2036.2007.03246.x]

31 **Tellez-Avila FI**, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. *World J Gastroenterol* 2008; **14**: 4771-4775 [PMID: 18720537 DOI: 10.3748/wjg.14.4771]

32 **Taura N**, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta M, Kawashimo H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Abiru N, Yamasaki H, Eguchi K. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. *Am J Gastroenterol* 2006; **101**: 2752-2759 [PMID: 17026566 DOI: 10.1111/j.1572-0241.2006.00835.x]

33 **Pattullo V**, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? *Liver Int* 2010; **30**: 356-364 [PMID: 20040049 DOI: 10.1111/j.1478-3231.2009.02185.x]

34 **Roden M**. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. *Nat Clin Pract Endocrinol Metab* 2006; **2**: 335-348 [PMID: 16932311 DOI: 10.1038/ncpendmet0190]

35 **Flisiak R**, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. *Cytokine* 2000; **12**: 677-681 [PMID: 10843744 DOI: 10.1006/cyto.1999.0660]

36 **Whitehead JP**, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin--a key adipokine in the metabolic syndrome. *Diabetes Obes Metab* 2006; **8**: 264-280 [PMID: 16634986 DOI: 10.1111/j.1463-1326.2005.00510.x]

37 **Bertolani C**, Marra F. The role of adipokines in liver fibrosis. *Pathophysiology* 2008; **15**: 91-101 [PMID: 18602801 DOI: 10.1016/j.pathophys.2008.05.001]

38 **Jonsson JR**, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. *J Hepatol* 2005; **43**: 929-936 [PMID: 16139921 DOI: 10.1016/j.jhep.2005.05.030]

39 **Svegliati-Baroni G**, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. *Hepatology* 1999; **29**: 1743-1751 [PMID: 10347117 DOI: 10.1002/hep.510290632]

40 **Hagel S**, Bruns T, Herrmann A, Stallmach A, Schmidt C. Abnormal glucose tolerance: a predictor of 30-day mortality in patients with decompensated liver cirrhosis. *Z Gastroenterol* 2011; **49**: 331-334 [PMID: 21391163 DOI: 10.1055/s-0029-1245933]

41 **Sorrentino P**, Tarantino G, Conca P, Perrella A, Perrella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. *Can J Gastroenterol* 2004; **18**: 381-386 [PMID: 15190393]

42 **Cheruvattath R**, Balan V. Infections in Patients With End-stage Liver Disease. *J Clin Gastroenterol* 2007; **41**: 403-411 [PMID: 17413611 DOI: 10.1097/01.mcg.0000248018.08515.f9]

43 **Moreau R**, Chagneau C, Heller J, Chevenne D, Langlet P, Deltenre P, Hillaire S, Lefilliatre P, Pateron D, Sogni P, Valla D, Lebrec D. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. *Scand J Gastroenterol* 2001; **36**: 303-308 [PMID: 11305519 DOI: 10.1080/003655201750074654]

44 **Thalheimer U**, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. *Gut* 2005; **54**: 556-563 [PMID: 15753544 DOI: 10.1136/gut.2004.048181]

45 **Kalaitzakis E**, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Jalan R, Björnsson E. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. *Liver Int* 2007; **27**: 1194-1201 [PMID: 17919230]

46 **Marchesini G**, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, Melchionda N. Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance. *Am J Gastroenterol* 1999; **94**: 655-662 [PMID: 10086647]

47 **Petta S**, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, Licata A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licata G, Craxì A. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. *Hepatology* 2012; **55**: 1317-1323 [PMID: 22135089 DOI: 10.1002/hep.25508]

48 **Adinolfi LE**, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. *Atherosclerosis* 2012; **221**: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]

**P-Reviewers:** Hee Y, Lonardo A, Perazzo H

**S-Editor:** Zhai HH **L-Editor: E-Editor:**

**Figure 1 Flowchart describing how selection of patients for the study was done.** LC: Liver cirrhosis; OGTT: Oral glucose tolerance test; IGT: Impaired glucose tolerance; DM: Diabetes mellitus.

**Figure 2 Cumulated survival of cirrhotic patients with normal glucose tolerance or subclinical abnormal glucose tolerance.** Note that significant differences between both groups are evident after 3 years of follow up.NGT: Normal glucose tolerance; SAGT: Subclinical abnormal glucose tolerance.

**Table 1 Clinical and biochemical characteristics of cirrhotic patients *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | Total (*n* = 100) | NGT (*n* = 30) | SAGT (*n* = 70) |
| Age, yr  | 53.9 ± 11.8 | 49.0 ± 12.0 | 56.0 ± 11.1 1 |
| BMI, kg/m2 | 26.9 ± 4.2 | 26.4 ± 4.40 | 27.21 ± 4.15 |
| Males, | 60 (60) | 18 (60) | 42 (60) |
| Etiology: Alcohol | 47(47) | 14 (46.6) | 33(47.1) |
|  HBV | 4(4) | 1 (3.3) | 3 (4.2)  |
|  HCV | 13 (13) | 2 (6.6) | 11(15.7) |
|  Autoimmunity | 10 (10) | 3 (10) | 7 (10) |
|  Cryptogenic | 26 (26) | 10 (33.3) | 16 (22.8) |
| Liver biopsy | 44 (44) | 13 (43.3) | 31 (44.2) |
| Length of LC, mo | 21.6 +27.6 | 21.4 ± 30.6 | 21.7 ± 33.2 |
| Hemoglobin , g/dL | 11.8 ± 2.3 | 11.6 ± 2.1 | 11.9 ± 2.3 |
| Platelets , x mm3 | 128140 ± 89,501 | 159186 ± 112,108 | 114,834 ± 73269 |
| INR | 1.3 ± 0.3 | 1.2 ± 0.3 | 1.36 ± .03 2 |
| Creatinine, mg/dL | 0.8 ± 0.2 | 0.90 ± 0.33 | 0.83 ± 0.2 |
| Albumin, g/dL | 3.2 ± 0.73 | 3.33 ± 0.71 | 3.21 ± 0.74 |
| ALT, UI /L | 46.5 ± 40.8 | 48.9 ± 53.9 | 45.4 ± 34. |
| Total bilirubin, mg/dL | 1.71 ± 0.90 | 1.55 ± 0.88 | 1.78 ± 0.91 |
| Fasting plasma insulin, µU/mL, | 15.9 ± 10.2 | 11.9 ± 7.6 | 18.2 ± 11 3 |
| HOMA2,score  | 2.67 ± 1.6 | 2.36 ± 1.46 | 4.6 ± 3.3 4 |
| Child-Pugh A | 47 (47) | 15 (50) | 32 (45.7) |
|  B  | 53 (53) | 15 (50) | 38 (54.2) |
| Child Pugh score | 6.8 ± 1.8 | 6.5 ± 1.61 | 6.82 ± 1.67 |
| MELD score,  | 8.94 ± 4.8 | 8.3 ± 5.2 | 9.21 ± 4.63 |
| Survival, d | 1237(990-1925) | 1448(1256-1925) | 1116(990-1790)5 |

Data are expressed as absolute numbers (percentage) or mean ± SD. 1*P* = 0.003; 2*P* = 0.025; 3*P* = 0.03; 4*P* = 0.009; 5*P* = 0.045. NGT: Normal glucose tolerance; SAGT: Subclinical abnormal glucose tolerance; HOMA: Homeostatic model assessment; LC: Liver cirrhosis.

**Table 2 Annual cumulated survival of cirrhotic patients *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| Years | NGT (*n* = 30) | SAGT (*n* = 70) | *P* value (χ*2* test) |
| 1 | 2 (93) | 9 (87) | 0.36 |
| 2 | 4 (83.2) | 14 (79) | 0.34 |
| 3 | 4 (83.2) | 23 (51.4) | *0.04* |
| 4 | 4 (83.2) | 24 (47.5) | *0.03* |
| 5 | 5 ( 71.6) | 26 (31.7) | *0.02* |

NGT: Normal glucose tolerance; SAGT: Subclinical abnormal glucose tolerance.

**Table 3 Causes of death *n* (%)**

|  |  |
| --- | --- |
| Cause | Total (*n* = 31) |
| Variceal bleeding | 8 (25.8) |
| Liver failure | 6 (19.3) |
| SBP e infection | 5 (16.2) |
| Hepatorenal syndrome | 5(16.2) |
| HCC | 4 (12.9) |
| Renal impairment | 2 (6.4) |
| Cardiovascular | 1 (3.2) |

SBP: Spontaneous bacterial peritonitis; HCC: Hepatocellular carcinoma.

**Table 4 Univariate and multivariate analysis: Independent predictors of death**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | HR | 95%CI  | *P* value | HR | CI 95%  | *P* value |
| Creatinine | 1.6 | 1.2-40.2 | 0.03 | 2.62 | 0.5-3.46 | 0.65 |
| Albumin | 3.4 | 1.8-22.3 | 0.015 | 6.3 | 0.4-32.1 | 0.18 |
| INR | 2.2 | 1.6-32.4 | 0.05 | 3.5 | 0.3-23.6 | 0.23 |
| Grup B of Child-Pugh | 7.2 | 3.4-33.0 | 0.0003 | 8.2 | 2.0-28.5 | 0.02 |
| Child Pugh score | 5.2 | 2.9-25.8 | 0.008 | 10.2 | 2.4-21.9 | 0.008 |
| MELD score | 8.1 | 4.2-18.7 | 0.001 | 12.3 | 6.4-33.6 | 0.001 |
| SAGT | 4.5 | 2.0-15.2 | 0.042 | 3.2 | 2.8-54.2 | 0.01 |
| Fasting serum insulin | 1.2 | 1.0-33.5 | 0.04 | 3.2 | 0.1-27.3 | 0.32 |

 MELD: Model for end stage liver disease; INR: International normalized ratio; SAGT: Subclinical abnormal glucose tolerance.